Genentech pays $200M for Vaccibody's phase 1 cancer vaccine

Genentech pays $200M for Vaccibody's phase 1 cancer vaccine

Source: 
Fierce Biotech
snippet: 

Genentech has secured a global license to neoantigen cancer vaccines developed by Vaccibody. The Roche subsidiary is set to hand over $200 million in upfront and near-term payments to access the fruits of Vaccibody’s efforts to overcome the limitations of cancer vaccines.